239P - Primary squamous cell carcinoma of the stomach (PSCCS) – A systematic review and meta-analysis

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Gastric Cancer
Presenter Antony Thottian
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors A.G. Thottian, B.P. Venkatesulu, S. Chaliyadan, G.K. Rath
  • Radiation Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN

Abstract

Background

PSCCS is a rare entity with less than 150 cases reported in the literature. This study was undertaken to identify the demographic profile, patterns of care and survival data in this subset of stomach cancer.

Methods

Full length papers of all cases of PSCCS reported and published in English from 1950 to 2016 were independently searched and retrieved by the authors from PUBMED, Google Search and Cochrane Library.

Results

32 studies with N = 91 were found to be eligible for meta-analysis. Eligibility criteria included full length papers, case series and reports, published in English language between 1950 and 2016. Only cases in which no other synchronous malignancy except for PSCCS were included. Median age of the cohort was 65 years (Range 17 – 83). 72 (79.1%) were male and 19 (20.9%) were female. 63 (69.2%) patients were of Asian origin and 28 (30.8%) were of non-Asian origin. The maximum bulk of the tumour was noted in the fundus/cardia of the stomach (n = 28, 35.4%), followed by body, pylorus/antrum and post gastrectomy stump. 20% of the patients were found to be metastatic upfront. 9 (9.9%) patients had identifiable risk factors for development of squamous cell carcinoma like radiation or corrosive injury, gastrectomy or cyclophosphamide intake. Surgery was the sole treatment in n = 27 (33%), adjuvant or neoadjuvant chemotherapy was delivered in n = 24 (29.6%) and palliative treatment in n = 15 (18.5%). Adjuvant or neo adjuvant therapy significantly improved progression free survival (PFS) but not overall survival (OS). The chemotherapy regimen administered was heterogeneous and the most effective regimen could not be identified. OS ranged from 0 to 72 months with median of 12 months. 3 year OS was 43%. Only T stage was found to be a significant factor for OS in univariate analysis (p = 0.029).

Conclusions

PSCCS is a rare entity with limited data available on causation or management strategies. Adjuvant or neoadjuvant chemotherapy in addition to surgery improves PFS.

Clinical trial indentification

Legal entity responsible for the study

AIIMS

Funding

AIIMS

Disclosure

All authors have declared no conflicts of interest.